Capromorelin
(Ghrelin)Phase 2Small molecule
Ghrelin is used to stimulate appetite and help people gain weight, particularly in cancer patients who have lost their appetite, and in dogs with poor appetite.[1] Capromorelin is currently being investigated across 11 indications[3], with its most advanced program in Phase 2.[1]
Capromorelin is one of 318 small molecule programs targeting Cachexia. It is currently in Phase 2.
11
Indications
20
Total Trials
0
Active Trials
317
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Capromorelin
UUniversity of Aarhus
Phase 2
Byetta
AstraZenecaPreclinical
Insulin 320
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Golytely
BayerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alcohol1 trial
Effects of Ghrelin on Alcohol Cue Reactivity and Craving
Completed·—·N/A·NCT01190085·45 enrolled
12 more indications
Endothelial Dysfunction1 trial
Heavy Drinker1 trial
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT01779024·17 enrolled
Cachexia1 trial
Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study
Completed·—·Phase 1/2·NCT00933361·21 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ghrelin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Aarhus